Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Zacks Investment Research • Jun 5, 2026

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

Launched on June 19, 2006, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

Zacks Investment Research • Jun 3, 2026

US FDA to review AI-based tool to predict drug-related liver damage

The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of intent for ​an artificial intelligence-based drug development tool designed to ‌help predict drug-induced liver injury.

Reuters • Jun 3, 2026

Trump to announce discount drug pricing expansion, White House official says

U.S. President Donald Trump will ‌announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his ​administration's pricing deal, on Monday, a White ​House official said.

Reuters • May 18, 2026

Medical Technology Stocks: Innovation Endures As Valuations Reset

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Seeking Alpha • May 2, 2026

US FDA to monitor clinical trial data in real time in pilot program aimed at speeding approvals

The U.S. ​Food and Drug Administration launched a pilot program on Monday aimed at allowing the ‌agency to monitor clinical trial data in real time, a step the agency said could cut years from drug approval timelines and keep the U.S. competitive with China.

Reuters • Apr 28, 2026

Could pressure to make money faster kill the next lifesaving pill?

When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.

Market Watch • Apr 15, 2026

Global PMI: Tracking The Sectors Hit Hardest By The Middle East War

Survey data underscored how the war in the Middle East has already had a material impact on economic growth around the world. Drilling down deeper, the data showed weaker growth trends were recorded across all major industries globally.

Seeking Alpha • Apr 12, 2026

Can Forgotten Biotech Break Out?

After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Biotech hasn't garnered much attention lately, with all the coverage of the Iran War and the AI Doom trade that's been taking down software stocks even as AI infrastructure stocks continue to surge.

Seeking Alpha • Apr 11, 2026

Trump's 100% Pharma Tariffs Will Have A Limited Effect On The Sector

On Thursday, news broke that the US will likely start levying a 100% tariff on branded pharmaceutical imports. The specifics remain unclear, but the levy is expected to be relatively narrow in scope, since many exemptions have already been negotiated.

Seeking Alpha • Apr 3, 2026